Industry Trend

Site Sections

Menu








© 2023. All Rights reserved.

Overview for GILEAD SCIENCES

All Data per May 26, 2023

Industry:

Drug Manufacturers—General

Last Close:

77.09 USD

Expected Dividend:

3.89 %

Payoffs per Year:

4
Business Summary
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.

Competitors View

Ordering

PFIZER

USA		 0.89 3.74%
4.36%		 6.07% 4.49% 1.0 0.61
-43.29%		 46.05 16.02% 48.64 1.0

ABBVIE

USA		 1.02 3.5%
4.3%		 10.17% 5.07% 1.0 3.15
-14.88%		 42.79 13.02% 12.45 2.0

ASTRAZENECA

GBR		 1.06 3.6%
2.11%		 5.97% 4.3% 0.5 16.21
-3.86%		 67.14 17.71% 38.41 3.0

SANOFI

FRA		 1.11 3.8%
3.58%		 1.59% 3.73% 1.0 0.88
-12.18%		 49.68 12.1% 59.3 4.0

CHUGAI PHARMACEUTICAL

JPN		 0.98 1.38%
2.08%		 16.13% 2.65% 1.0 3.06
-38.8%		 42.96 15.38% 77.21 5.0

MERCK & CO.

USA		 1.09 3.4%
2.67%		 5.29% 3.94% 1.0 3.67
-11.68%		 47.47 8.91% 42.19 6.0

BRISTOL-MYERS SQUIBB

USA		 0.95 2.6%
4.47%		 2.48% 2.66% 1.0 0.53
-24.44%		 34.16 17.14% 32.14 7.0

ASTELLAS PHARMA

JPN		 1.01 2.35%
2.85%		 19.78% 5.38% 1.0 1.47
-19.06%		 31.03 -2.41% 62.61 8.0

ELI LILLY AND COMPANY

USA		 1.1 2.36%
1.06%		 14.8% 4.25% 1.0 11.83
-12.71%		 45.05 7.83% 21.77 9.0

AMGEN

USA		 0.95 2.75%
3.93%		 10.11% 3.97% 1.0 1.83
-17.4%		 38.25 -3.13% 5.62 10.0

DAIICHI SANKYO

JPN		 1.07 2.05%
0.7%		 6.06% 2.46% 1.0 10.21
-17.26%		 41.99 11.62% 60.81 11.0

KYOWA HAKKO KOGYO

JPN		 0.95 1.65%
1.91%		 8.0% 2.16% 1.0 3.07
-15.61%		 44.19 3.67% 81.16 12.0

OTSUKA HOLDINGS CO., LTD.

JPN		 1.01 2.16%
1.93%		 0.0% 1.98% 1.0 0.44
-14.62%		 29.23 12.66% 72.92 13.0

ROCHE

CHE		 0.92 3.1%
3.27%		 1.69% 3.06% 1.0 0.55
-23.37%		 40.4 0.0% 36.32 14.0

GILEAD SCIENCES

USA
 1.04 3.5%
3.89%		 3.61% 3.76% 0.5 0.24
-42.43%		 36.76 3.95% 33.57 15.0

JOHNSON & JOHNSON

USA		 0.96 2.69%
3.05%		 5.9% 3.2% 1.0 0.19
-12.62%		 46.37 -0.95% 40.99 16.0

BAYER

GER		 1.06 2.96%
3.68%		 0.81% 2.81% 0.5 -0.3
-58.76%		 37.48 -6.72% 31.17 17.0

GLAXOSMITHKLINE

GBR		 1.02 6.49%
2.62%		 0.0% 5.95% -1.0 0.02
-24.56%		 47.0 -2.84% 16.79 18.0

GRIFOLS SA

ESP		 0.91 1.1%
0.0%		 -53.18% 0.2% -0.5 -0.11
-65.73%		 32.66 2.01% 38.04 19.0

Information for GILEAD SCIENCES

Yield Triangle

Dividend & Close

Dividend Close Div.-Yield
Year
2023 3.00 77.09 3.89
2022 2.92 85.85 3.40
2021 2.84 72.61 3.91
2020 2.72 58.26 4.67
2019 2.52 64.98 3.88
2018 2.28 61.88 3.68
2017 2.08 71.64 2.90
2016 1.84 71.61 2.57
2015 1.29 101.19 1.27

Fundamentals

Chart